OTSUKA HOLDINGS CO LTD- UNSP Business Summary

Otsuka Holdings Co., Ltd. operates as a global "total healthcare" enterprise, generating revenue through a diversified portfolio across four primary segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceutical division focuses on high-value therapeutic areas including central nervous system (CNS) disorders, oncology, and nephrology, driven by flagship products like Rexulti, Abilify Maintena, and the recently approved Voyxact. The Nutraceutical segment leverages iconic brands such as Pocari Sweat and Nature Made to capture the functional food and supplement markets. As of July 31, 2026, the company reported strong second-quarter results, raising its full-year guidance due to robust drug sales and strategic expansion in the U.S. market. Otsuka competes directly with major Japanese peers such as Takeda Pharmaceutical, Astellas Pharma, and Daiichi Sankyo, positioning itself as a unique hybrid that balances high-risk R&D innovation with the steady, cash-generative stability of consumer health brands. The leadership team is currently led by Makoto Inoue, who assumed the role of President and CEO in January 2025 after serving as the head of the group’s main pharmaceutical subsidiary. He is supported by Chairman Ichiro Otsuka, a descendant of the founding family who maintains the company’s long-term "Big Venture" philosophy, and Yuko Makino, the Senior Executive Director and CFO responsible for the group's capital allocation and financial strategy. The executive board is characterized by deep internal pedigree, with most members having decades of experience within the Otsuka Group’s various global divisions. Publicly traded on the Tokyo Stock Exchange, the company maintains a stable institutional investor base including major global asset managers and Japanese financial institutions, reflecting its status as a cornerstone of the international healthcare sector.